Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

TCT 2021 | PTCy in MMUD HCT: the University of Miami experience

Name: PTCy in MMUD HCT: the University of Miami experience
Uploaded: 2021-02-17T00:00:00Z
Duration: 5 min 38 s

Muhammad Husnain • 17 Feb 2021

TCT 2021

General Cyclophosphamide

Muhammad Husnain, MD, University of Arizona, Arizona Cancer Center, Tucson, AZ, outlines the impact of graft-vs-host disease (GvHD) prophylaxis using anti-thymocyte globulin (ATG) versus post-transplant cyclophosphamide (PTCy), on clinical outcomes following HLA-mismatched unrelated donor (MMUD) hematopoietic stem cell transplantation (HCT). Despite a higher degree of HLA-mismatch, PTCy following mismatched unrelated donor HCT resulted in superior overall survival, relapse-free survival, and lower non-relapse mortality compared to ATG-based prophylaxis. This interview took place during the Transplantation & Cellular Therapy (TCT) 2021 Meetings.